

IN A RANDOMIZED CONTROLLED TRIAL, PROVANT® THERAPY RESULTED IN A CLINICALLY MEANINGFUL REDUCTION IN BACK PAIN


Patients were in persistent pain following lumbar surgery

April 2018 News Update


Up to 30% of back surgery patients experience pain beyond the acute postoperative period. This may lead to reduced physical function, increased opioid use, and expensive ancillary procedures. A randomized controlled clinical trial showed subjects treated with Provant Therapy had a clinically meaningful reduction in average low back pain and leg pain.

Subjects treated twice a day for 60 days. Pain was reported on the 11-point scale. Two groups are reported on here: Active and Sham. Clinically meaningful pain reduction is defined as 30%.

BACK PAIN: Active Provant Therapy Achieved Clinically Meaningful Pain Reduction



LEG PAIN: Active Provant Therapy Achieved Clinically Meaningful Pain Reduction



The journal article discussing the complete results of the clinical trial is in press. We will notify you once published.

For postoperative pain relief, consider Provant Therapy, which is safe, non-drug pain management. Provant is high-energy, dual-field electromagnetic therapy. To learn more, please contact your Regenesi Biomedical representative, or visit www.regenesibio.com. You can keep up with the latest pain management news by clicking these links to follow us on social media:



If you have colleagues that would like to receive these monthly newsletters, please forward this email to them; they may subscribe by emailing us at newsletter@regenesisbio.com

Sources

1. Manchikanti, L. et al. Contribution of Facet Joints to Chronic Low Back Pain in Postlumbar Laminectomy Syndrome: A Controlled Comparative Prevalence Evaluation. *Pain Physician*, Volume 4, Number 2, pp 175-180, 2001.
2. Chan and Peng. Review article: Failed back surgery syndrome. *Pain Medicine* 2011; 12: 577–606.
3. Parker, S. et al. Long-term back pain after a single-level discectomy for radiculopathy: incidence and health care cost analysis. *J Neurosurg Spine* 12:178–182, 2010.